Literature DB >> 10029082

Improvement of systemic 5-aminolevulinic acid-based photodynamic therapy in vivo using light fractionation with a 75-minute interval.

H S de Bruijn1, N van der Veen, D J Robinson, W M Star.   

Abstract

We have studied different single and fractionated illumination schemes after systemic administration of 5-aminolevulinic acid (ALA) to Improve the response of nodular tumors to ALA-mediated photodynamic therapy. Tumors transplanted on the thigh of female WAG/Rij rats were transdermally illuminated with red light (633 nm) after systemic ALA administration (200 mg/kg). The effectiveness of each treatment scheme was determined from the tumor volume doubling time. A single illumination (100 J/cm2 at 100 mW/cm2, 2.5 h after ALA administration) yielded a doubling time of 6.6+/-1.2 days. This was significantly different from the untreated control (doubling time, 1.7+/-0.1 days). The only treatment scheme that yielded a significant improvement compared to all other schemes studied was illumination at both 1 and 2.5 h after ALA administration (both 100 J/cm2 at 100 mW/cm2) and resulted in a tumor volume doubling time of 18.9+/-2.9 days. A possible mechanism to explain this phenomenon is that the protoporphyrin IX formed after administration of ALA is photodegraded by the first illumination. In the 75-min interval, new porphyrin is formed enhancing the effect of the second illumination.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029082

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  In vivo evaluation of battery-operated light-emitting diode-based photodynamic therapy efficacy using tumor volume and biomarker expression as endpoints.

Authors:  Srivalleesha Mallidi; Zhiming Mai; Imran Rizvi; Joshua Hempstead; Stephen Arnason; Jonathan Celli; Tayyaba Hasan
Journal:  J Biomed Opt       Date:  2015-04       Impact factor: 3.170

Review 2.  Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives.

Authors:  F S De Rosa; M V Bentley
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

Review 3.  Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions.

Authors:  Demian van Straten; Vida Mashayekhi; Henriette S de Bruijn; Sabrina Oliveira; Dominic J Robinson
Journal:  Cancers (Basel)       Date:  2017-02-18       Impact factor: 6.639

4.  Light Fractionation Significantly Increases the Efficacy of Photodynamic Therapy Using BF-200 ALA in Normal Mouse Skin.

Authors:  Henriëtte S de Bruijn; Sander Brooks; Angélique van der Ploeg-van den Heuvel; Timo L M Ten Hagen; Ellen R M de Haas; Dominic J Robinson
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

5.  Effects of light fractionation and different fluence rates on photodynamic therapy with 5-aminolaevulinic acid in vivo.

Authors:  P Babilas; V Schacht; G Liebsch; O S Wolfbeis; M Landthaler; R-M Szeimies; C Abels
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

6.  Porphyrin accumulation induced by 5-aminolaevulinic acid esters in tumour cells growing in vitro and in vivo.

Authors:  R G Tunstall; A A Barnett; J Schofield; J Griffiths; D I Vernon; S B Brown; D J H Roberts
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

7.  Enhanced effects of aminolaevulinic acid-based photodynamic therapy through local hyperthermia in rat tumours.

Authors:  D K Kelleher; J Bastian; O Thews; P Vaupel
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

8.  Targets and mechanisms of photodynamic therapy in lung cancer cells: a brief overview.

Authors:  Angela Chiaviello; Ilaria Postiglione; Giuseppe Palumbo
Journal:  Cancers (Basel)       Date:  2011-03-03       Impact factor: 6.639

9.  Blood Flow Measurements Enable Optimization of Light Delivery for Personalized Photodynamic Therapy.

Authors:  Yi Hong Ong; Joann Miller; Min Yuan; Malavika Chandra; Mirna El Khatib; Sergei A Vinogradov; Mary E Putt; Timothy C Zhu; Keith A Cengel; Arjun G Yodh; Theresa M Busch
Journal:  Cancers (Basel)       Date:  2020-06-15       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.